Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EAU 2025 | Perioperative outcomes of single- versus multi-port robotic prostatectomy

Alessandro Bertini • 28 Feb 2025
EAU 2025
Genitourinary Cancer Prostate Cancer

Alessandro Bertini, MD, IRCCS Ospedale San Raffaele, Milan, Italy & Henry Ford Health System, Detroit, MI, describes a multicenter propensity score-matched analysis comparing perioperative outcomes of single-port (SP) and multi-port (MP) robotic-assisted radical prostatectomy (RALP). Findings suggest that SP-RALP is associated with shorter operative time, and decreased length of stay, though it has a higher rate of positive surgical margins. No significant differences were observed in postoperative complications. This interview took place at the 2025 European Association of Urology (EAU) Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Alessandro Bertini

Assessing the incidence of bladder cancer during the COVID-19 pandemic
2:16
Assessing the incidence of bladder cancer during the COVID-19 pandemic
Alessandro Bertini • 28 Feb 2025
Long-term outcomes of PSA persistence after robotic prostatectomy
1:49
Long-term outcomes of PSA persistence after robotic prostatectomy
Alessandro Bertini • 28 Feb 2025
The impact of socioeconomic deprivation in oncological outcomes
2:23
The impact of socioeconomic deprivation in oncological outcomes
Alessandro Bertini • 28 Feb 2025
Socioeconomic disparities in quality of surgery in patients with MIBC
2:57
Socioeconomic disparities in quality of surgery in patients with MIBC
Alessandro Bertini • 28 Feb 2025

Related Videos

Emerging insights on TKI-associated muscle loss in renal cell carcinoma
1:14
Emerging insights on TKI-associated muscle loss in renal cell carcinoma
Andrew Hahn • 31 May 2026
Balancing efficacy and tolerability in second-line RCC treatment
1:17
Balancing efficacy and tolerability in second-line RCC treatment
Andrew Hahn • 31 May 2026
LenCabo: body composition and QoL with lenvatinib and everolimus in ccRCC
2:07
LenCabo: body composition and QoL with lenvatinib and everolimus in ccRCC
Andrew Hahn • 31 May 2026
Real-world outcomes by HER2 expression in la/mUC in the SGNDV-003 study
5:25
Real-world outcomes by HER2 expression in la/mUC in the SGNDV-003 study
Vadim Koshkin • 1 Jun 2026
The content of VJOncology is intended for healthcare professionals